



CODE/NAME & ADDRESS: C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO: **0251WB002104**PATIENT ID: 0MPRM250289251

CLIENT PATIENT ID: 012302250020

ABHA NO :

AGE/SEX :34 Years Male
DRAWN :25/02/2023 09:04:00
RECEIVED :25/02/2023 12:23:08
REPORTED :25/02/2023 16:38:18

Test Report Status	<u>Preliminary</u>	Results	Biological Reference Interval Units	

H	AEMATOLOGY - CBC		
MEDI WHEEL FULL BODY HEALTH CHECK UP BE	LOW 40 MALE		
BLOOD COUNTS,EDTA WHOLE BLOOD			
HEMOGLOBIN (HB)	14.3	13.0 - 17.0	g/dL
METHOD: CYANIDE FREE DETERMINATION			
RED BLOOD CELL (RBC) COUNT METHOD: ELECTRICAL IMPEDANCE	4.87	4.5 - 5.5	mi l /μL
WHITE BLOOD CELL (WBC) COUNT METHOD: ELECTRICAL IMPEDANCE	7.50	4.0 - 10.0	thou/µL
PLATELET COUNT	223	150 - 410	thou/µL
METHOD: ELECTRONIC IMPEDANCE			
RBC AND PLATELET INDICES			
HEMATOCRIT (PCV)	43.0	40 - 50	%
METHOD: CALCULATED PARAMETER			a.
MEAN CORPUSCULAR VOLUME (MCV)	88.0	83 - 101	fL
MEAN CORRUSCHUAR HEMOCLORIN (MCH)	29.3	27.0 - 32.0	na
MEAN CORPUSCULAR HEMOGLOBIN (MCH) METHOD: CALCULATED PARAMETER	29.3	27.0 - 32.0	pg
MEAN CORPUSCULAR HEMOGLOBIN	33.2	31.5 - 34.5	g/dL
CONCENTRATION (MCHC) METHOD: CALCULATED PARAMETER			
RED CELL DISTRIBUTION WIDTH (RDW)	13.0	11.6 - 14.0	%
METHOD: CALCULATED PARAMETER			
MENTZER INDEX	18.1		
MEAN PLATELET VOLUME (MPV)	12.7 High	6.8 - 10.9	fL
METHOD: CALCULATED PARAMETER			
WBC DIFFERENTIAL COUNT			
NEUTROPHILS	60	40 - 80	%
METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY			0/
LYMPHOCYTES	28	20 - 40	%
METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY	0.0	2 10	0/
MONOCYTES METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY	06	2 - 10	%
EOSINOPHILS	06	1 - 6	%
METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY	00	1 0	,,

Dr. Akanaha I

Dr. Akansha Jain Consultant Pathologist





Page 1 Of 13

View Details











CODE/NAME & ADDRESS: C000049066 SRL JAIPUR WELLNESS CORPORATE WALK IN AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100

ACCESSION NO: 0251WB002104 PATIENT ID : OMPRM250289251 CLIENT PATIENT ID: 012302250020

ABHA NO

AGE/SEX :34 Years Male :25/02/2023 09:04:00 DRAWN RECEIVED : 25/02/2023 12:23:08 REPORTED :25/02/2023 16:38:18

Test Report Status <u>Preliminary</u>	Results	Biological Reference	Interval Units
BASOPHILS	00	0 - 2	%
METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY	00	0 - 2	70
ABSOLUTE NEUTROPHIL COUNT METHOD: CALCULATED PARAMETER	4.5	2.0 - 7.0	thou/µL
ABSOLUTE LYMPHOCYTE COUNT METHOD: CALCULATED PARAMETER	2.1	1.0 - 3.0	thou/µL
ABSOLUTE MONOCYTE COUNT METHOD: CALCULATED PARAMETER	0.45	0.2 - 1.0	thou/µL
ABSOLUTE EOSINOPHIL COUNT METHOD: CALCULATED PARAMETER	0.45	0.02 - 0.50	thou/µL
ABSOLUTE BASOPHIL COUNT	0 Low	0.02 - 0.10	thou/µL
NEUTROPHIL LYMPHOCYTE RATIO (NLR)	2.1		

Interpretation(s)
BLOOD COUNTS, EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for

diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

Dr. Akansha Jain **Consultant Pathologist** Page 2 Of 13













REF. DOCTOR: SELF **PATIENT NAME: OM PRAKASH**

CODE/NAME & ADDRESS: C000049066 SRL JAIPUR WELLNESS CORPORATE WALK IN AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100

ACCESSION NO: 0251WB002104 PATIENT ID : OMPRM250289251

CLIENT PATIENT ID: 012302250020

ABHA NO

AGE/SEX :34 Years Male DRAWN :25/02/2023 09:04:00 RECEIVED: 25/02/2023 12:23:08

REPORTED :25/02/2023 16:38:18

Biological Reference Interval **Test Report Status** Results **Preliminary** Units

HAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD

E.S.R 0 - 14mm at 1 hr

METHOD: AUTOMATED (PHOTOMETRICAL CAPILLARY STOPPED FLOW KINETIC ANALYSIS)"

Interpretation(s)

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays' fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change. **TEST INTERPRETATION**

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging,

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias,

Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis). In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum. Decreased in: Polycythermia vera, Sickle cell anemia

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc.), Hypercholesterolemia
False Decreased: Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine,

salicylates)

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition.

Dr. Akansha Jain Consultant Pathologist





Page 3 Of 13





CODE/NAME & ADDRESS: C000049066 SRL JAIPUR WELLNESS CORPORATE WALK IN AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100

ACCESSION NO: 0251WB002104 PATIENT ID : OMPRM250289251

CLIENT PATIENT ID: 012302250020

AGE/SEX :34 Years Male DRAWN :25/02/2023 09:04:00 RECEIVED : 25/02/2023 12:23:08

REPORTED :25/02/2023 16:38:18

Test Report Status Results **Biological Reference Interval Units Preliminary**

ABHA NO

IMMUNOHAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP TYPE A

METHOD: TUBE AGGLUTINATION

POSITIVE RH TYPE

METHOD: TUBE AGGLUTINATION

Interpretation(s)

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same.'

The test is performed by both forward as well as reverse grouping methods.

Dr. Akansha Jain **Consultant Pathologist**



Page 4 Of 13









CODE/NAME & ADDRESS: C000049066 SRL JAIPUR WELLNESS CORPORATE WALK IN AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100

ACCESSION NO: 0251WB002104 PATIENT ID : OMPRM250289251 CLIENT PATIENT ID: 012302250020

ABHA NO

AGE/SEX :34 Years Male DRAWN :25/02/2023 09:04:00 RECEIVED: 25/02/2023 12:23:08 REPORTED :25/02/2023 16:38:18

Test Report Status Results **Biological Reference Interval Units Preliminary**

BIOCHEMISTRY	
---------------------	--

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

GLUCOSE FASTING, FLUORIDE PLASMA

FBS (FASTING BLOOD SUGAR) 111 High 74 - 99 mg/dL

METHOD: GLUCOSE OXIDASE

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE

BLOOD

HBA1C 5.7 Non-diabetic: < 5.7 %

> Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5Therapeutic goals: < 7.0 Action suggested: > 8.0 (ADA Guideline 2021)

METHOD: HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC)

ESTIMATED AVERAGE GLUCOSE(EAG) 116.9 High < 116.0 mg/dL

METHOD: CALCULATED PARAMETER

GLUCOSE, POST-PRANDIAL, PLASMA

PPBS(POST PRANDIAL BLOOD SUGAR) 101 70 - 140mg/dL

 ${\tt METHOD}: {\tt GLUCOSE} \ {\tt OXIDASE}$ LIPID PROFILE, SERUM

METHOD: CHOLESTEROL OXIDASE

154

< 200 Desirable mg/dL CHOLESTEROL, TOTAL

200 - 239 Borderline High

>/= 240 High

TRIGLYCERIDES 75 < 150 Normal mg/dL

150 - 199 Borderline High

200 - 499 High >/=500 Very High

METHOD: LIPASE/GPO-PAP NO CORRECTION

< 40 Low mg/dL HDL CHOLESTEROL 44

>/=60 High

METHOD: DIRECT CLEARANCE METHOD

Dr. Akansha Jain **Consultant Pathologist**



Page 5 Of 13









CODE/NAME & ADDRESS: C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO: **0251WB002104**PATIENT ID: OMPRM250289251

CLIENT PATIENT ID: 012302250020

ABHA NO :

AGE/SEX :34 Years Male
DRAWN :25/02/2023 09:04:00
RECEIVED :25/02/2023 12:23:08
REPORTED :25/02/2023 16:38:18

	i		
Test Report Status <u>Preliminary</u>	Results	Biological Reference In	terval Units
CHOLESTEROL LDL	96	< 100 Optimal 100 - 129 Near optimal/ above op 130 - 159 Borderline High 160 - 189 High >/= 190 Very High	mg/dL otimal
NON HDL CHOLESTEROL	110	Desirable: Less than 1: Above Desirable: 130 - Borderline High: 160 - High: 190 - 219 Very high: > or = 220	- 159 189
METHOD: CALCULATED PARAMETER		, 3	
VERY LOW DENSITY LIPOPROTEIN	15.0	= 30.0</td <td>mg/dL</td>	mg/dL
CHOL/HDL RATIO	3.5	3.3 - 4.4 Low Risk 4.5 - 7.0 Average Risk 7.1 - 11.0 Moderate Risk > 11.0 High Risk	
LDL/HDL RATIO	2.2	0.5 - 3.0 Desirable/Lov 3.1 - 6.0 Borderline/Mo Risk >6.0 High Risk	
Interpretation(s)			
LIVER FUNCTION PROFILE, SERUM			
BILIRUBIN, TOTAL METHOD: DIAZO WITH SULPHANILIC ACID	0.45	0 - 1	mg/dL
BILIRUBIN, DIRECT METHOD: DIAZO WITH SULPHANILIC ACID	0.22	0.00 - 0.25	mg/dL
BILIRUBIN, INDIRECT METHOD: CALCULATED PARAMETER	0.23	0.1 - 1.0	mg/dL
TOTAL PROTEIN METHOD: BIURET REACTION, END POINT	8.0	6.4 - 8.2	g/dL
ALBUMIN	4.4	3.8 - 4.4	g/dL

Dr. Akansha Jain

Consultant Pathologist



Page 6 Of 13

View Details













CODE/NAME & ADDRESS: C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO: **0251WB002104**PATIENT ID: 0MPRM250289251

CLIENT PATIENT ID: 012302250020

ABHA NO :

AGE/SEX :34 Years Male
DRAWN :25/02/2023 09:04:00
RECEIVED :25/02/2023 12:23:08
REPORTED :25/02/2023 16:38:18

	<u> </u>	<u> </u>	
Test Report Status <u>Preliminary</u>	Results	Biological Reference	Interval Units
METHOD : BROMOCRESOL GREEN			
GLOBULIN	3.6	2.0 - 4.1	g/dL
METHOD : CALCULATED PARAMETER	5.0	2.0 - 4.1	9,42
ALBUMIN/GLOBULIN RATIO METHOD: CALCULATED PARAMETER	1.2	1.0 - 2.1	RATIO
ASPARTATE AMINOTRANSFERASE (AST/SGOT) METHOD: TRIS BUFFER NO P5P IFCC / SFBC 37° C	36	0 - 37	U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT) METHOD: TRIS BUFFER NO P5P IFCC / SFBC 37° C	80 High	0 - 40	U/L
ALKALINE PHOSPHATASE METHOD: AMP OPTIMISED TO IFCC 37° C	64	39 - 117	U/L
GAMMA GLUTAMYL TRANSFERASE (GGT) METHOD: GAMMA GLUTAMYL-3 CARBOXY-4 NITROANILIDE (IFCC)	59 High) 37° C	11 - 50	U/L
LACTATE DEHYDROGENASE	364	230 - 460	U/L
BLOOD UREA NITROGEN (BUN), SERUM			
BLOOD UREA NITROGEN METHOD: UREASE KINETIC	14	5.0 - 18.0	mg/dL
CREATININE, SERUM			
CREATININE METHOD: ALKALINE PICRATE NO DEPROTEINIZATION	1.03	0.8 - 1.3	mg/dL
BUN/CREAT RATIO			
BUN/CREAT RATIO METHOD: CALCULATED PARAMETER	13.59		
URIC ACID, SERUM			
URIC ACID METHOD: URICASE PEROXIDASE WITH ASCORBATE OXIDASE	7.8 High	3.4 - 7.0	mg/dL
TOTAL PROTEIN, SERUM			
TOTAL PROTEIN METHOD: BIURET REACTION, END POINT	8.0	6.4 - 8.3	g/dL
ALBUMIN, SERUM			
ALBUMIN	4.4	3.8 - 4.4	g/dL
METHOD: BROMOCRESOL GREEN			-
GLOBULIN			
GLOBULIN	3.6	2.0 - 4.1	g/dL

Dr. Akansha Jain Consultant Pathologist





Page 7 Of 13

View Details











REF. DOCTOR: SELF **PATIENT NAME: OM PRAKASH**

CODE/NAME & ADDRESS: C000049066 SRL JAIPUR WELLNESS CORPORATE WALK IN AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100

ACCESSION NO: 0251WB002104 PATIENT ID : OMPRM250289251 CLIENT PATIENT ID: 012302250020

ABHA NO

AGE/SEX :34 Years Male DRAWN :25/02/2023 09:04:00 RECEIVED: 25/02/2023 12:23:08 REPORTED: 25/02/2023 16:38:18

·			
Test Report Status <u>Preliminary</u>	Results	Biological Referenc	e Interval Units
ELECTROLYTES (NA/K/CL), SERUM			
SODIUM, SERUM METHOD: ION-SELECTIVE ELECTRODE	140.2	137 - 145	mmo l /L
POTASSIUM, SERUM METHOD: ION-SELECTIVE ELECTRODE	4.65	3.6 - 5.0	mmo l /L
CHLORIDE, SERUM METHOD: ION-SELECTIVE ELECTRODE	106.0	98 - 107	mmo l /L
Interpretation(s)			

Interpretation(s)
GLUCOSE FASTING,FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the urine.

Increased in

Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides. **Decreased in**

Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency, hypopituitarism,diffuse liver disease, malignancy (adrenocortical, stomach, fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases(e.g., galactosemia), Drugs-insulin, ethanol, propranolol; sulfonylureas, tolbutamide, and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-Used For:

- 1.Evaluating the long-term control of blood glucose concentrations in diabetic patients.
- 2.Diagnosing diabetes.
 3.Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range. 1.eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.

- 2. eAG gives an evaluation of blood glucose levels for the last couple of months. 3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c 46.7

HbA1c Estimation can get affected due to :

I.Shortened Erythrocyte survival: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.

II. Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.

III. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates

addiction are reported to interfere with some assay methods, falsely increasing results. IV.Interference of hemoglobinopathies in HbA1c estimation is seen in

a.Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c. b.Heterozygous state detected (D10 is corrected for HbS & HbC trait.)

c.HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy
GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin

treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-LIVER FUNCTION PROFILE

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give

Dr. Akansha Jain **Consultant Pathologist** Page 8 Of 13







View Report







REF. DOCTOR: SELF **PATIENT NAME: OM PRAKASH**

CODE/NAME & ADDRESS: C000049066 SRL JAIPUR WELLNESS CORPORATE WALK IN AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100

ACCESSION NO: 0251WB002104 PATIENT ID : OMPRM250289251 CLIENT PATIENT ID: 012302250020

ABHA NO

AGE/SEX :34 Years Male DRAWN :25/02/2023 09:04:00 RECEIVED: 25/02/2023 12:23:08

REPORTED :25/02/2023 16:38:18

Test Report Status Results Biological Reference Interval Units **Preliminary**

yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood ALT is found mainly in the liver, but also in smaller amounts in the kidneys,heart,muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health AST levels increase during acute hepatitis, sometimes due to a viral infection, is chemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Paget''''s disease,Rickets,Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia,Malnutrition,Protein deficiency,Wilson'''s disease.GGT is an enzyme found in cell membranes of many tissues mainly in the liver,kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc. Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom'''s disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc. Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing

enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)
Causes of decreased level include Liver disease, SIADH.
CREATININE, SERUM-Higher than normal level may be due to:

Blockage in the urinary tract

- Kidney problems, such as kidney damage or failure, infection, or reduced blood flow
 Loss of body fluid (dehydration)
- Muscle problems, such as breakdown of muscle fibers
- Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to:

- Myasthenia Gravis
- Muscular dystrophy

URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake, Prolonged Fasting, Rapid weight loss), Gout, Lesch nyhan syndrome, Type 2 DM, Metabolic

Causes of decreased levels-Low Zinc intake.OCP.Multiple Sclerosis

TOTAL PROTEIN, SERUM-Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom"""""" s disease Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc.

Dr. Akansha Jain Consultant Pathologist Page 9 Of 13





View Details







CODE/NAME & ADDRESS: C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO: **0251WB002104**PATIENT ID: OMPRM250289251

CLIENT PATIENT ID: 012302250020

ABHA NO :

AGE/SEX :34 Years Male
DRAWN :25/02/2023 09:04:00
RECEIVED :25/02/2023 12:23:08
REPORTED :25/02/2023 16:38:18

Test Report Status <u>Preliminary</u> Results Biological Reference Interval Units

CLINICAL PATH - URINALYSIS

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

PHYSICAL EXAMINATION, URINE

COLOR PALE YELLOW

METHOD: GROSS EXAMINATION

APPEARANCE CLEAR

METHOD: GROSS EXAMINATION

CHEMICAL EXAMINATION, URINE

PH 6.5 4.7 - 7.5

METHOD: DOUBLE INDICATOR PRINCIPLE

SPECIFIC GRAVITY 1,020 1,003 - 1,035

METHOD: IONIC CONCENTRATION METHOD

PROTEIN NOT DETECTED NOT DETECTED

METHOD: PROTEIN ERROR OF INDICATORS WITH REFLECTANCE

GLUCOSE NOT DETECTED NOT DETECTED

METHOD : GLUCOSE OXIDASE PEROXIDASE / BENEDICTS

KETONES NOT DETECTED NOT DETECTED

 ${\tt METHOD: SODIUM\ NITROPRUSSIDE\ REACTION}$

METHOD: PEROCIDASE ANTI PEROXIDASE

BLOOD NOT DETECTED NOT DETECTED

BILIRUBIN NOT DETECTED NOT DETECTED

METHOD : DIPSTICK

UROBILINOGEN NORMAL NORMAL

METHOD: EHRLICH REACTION REFLECTANCE

NITRITE NOT DETECTED NOT DETECTED

METHOD: NITRATE TO NITRITE CONVERSION METHOD

LEUKOCYTE ESTERASE NOT DETECTED NOT DETECTED

MICROSCOPIC EXAMINATION, URINE

RED BLOOD CELLS NOT DETECTED NOT DETECTED /HPF

METHOD: MICROSCOPIC EXAMINATION

PUS CELL (WBC'S) 2-3 0-5 /HPF

METHOD : DIPSTICK, MICROSCOPY

EPITHELIAL CELLS 0-1 0-5 /HPF

EPITHELIAL CELLS 0-1 0-5 /HP

METHOD: MICROSCOPIC EXAMINATION

CASTS NOT DETECTED

Dr. Akansha Jain Consultant Pathologist



Page 10 Of 13













CODE/NAME & ADDRESS: C000049066 SRL JAIPUR WELLNESS CORPORATE WALK IN AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100

ACCESSION NO: 0251WB002104 PATIENT ID : OMPRM250289251 CLIENT PATIENT ID: 012302250020

ABHA NO

AGE/SEX :34 Years Male :25/02/2023 09:04:00 DRAWN RECEIVED : 25/02/2023 12:23:08

REPORTED :25/02/2023 16:38:18

Test Report Status Results Biological Reference Interval Units **Preliminary**

METHOD: MICROSCOPIC EXAMINATION

NOT DETECTED **CRYSTALS**

METHOD: MICROSCOPIC EXAMINATION

METHOD: MICROSCOPIC EXAMINATION

BACTERIA NOT DETECTED NOT DETECTED

YEAST **NOT DETECTED** NOT DETECTED

Interpretation(s)

Dr. Akansha Jain **Consultant Pathologist**



Page 11 Of 13



DIAGNOSTIC REPORT





PATIENT NAME: OM PRAKASH REF. DOCTOR: SELF

CODE/NAME & ADDRESS: C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO: **0251WB002104**PATIENT ID: OMPRM250289251

CLIENT PATIENT ID: 012302250020

ABHA NO

AGE/SEX :34 Years Male
DRAWN :25/02/2023 09:04:00
RECEIVED :25/02/2023 12:23:08

REPORTED :25/02/2023 16:38:18

Test Report Status Preliminary Results Biological Reference Interval Units

CLINICAL PATH - STOOL ANALYSIS

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOWE MATE DING
PHYSICAL EXAMINATION, STOOL RESULT PENDING
CHEMICAL EXAMINATION, STOOL RESULT PENDING
MICROSCOPIC EXAMINATION, STOOL RESULT PENDING

Page 12 Of 13





View Details







CODE/NAME & ADDRESS: C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO: **0251WB002104**PATIENT ID: OMPRM250289251

CLIENT PATIENT ID: 012302250020

ABHA NO :

AGE/SEX :34 Years Male
DRAWN :25/02/2023 09:04:00
RECEIVED :25/02/2023 12:23:08

REPORTED :25/02/2023 16:38:18

Test Report Status <u>Preliminary</u> Results Biological Reference Interval Units

SPECIALISED CHEMISTRY - HORMONE

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

THYROID PANEL, SERUM

T3	93.57	60.0 - 181.0	ng/dL
T4	7.50	4.5 - 10.9	μg/dL
TSH (ULTRASENSITIVE)	3.411	0.550 - 4.780	μIU/mL

End Of Report
Please visit www.srlworld.com for related Test Information for this accession

CONDITIONS OF LABORATORY TESTING & REPORTING

- 1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
- 2. All tests are performed and reported as per the turnaround time stated in the SRL Directory of Services.3. Result delays could occur due to unforeseen
- circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.
- 4. A requested test might not be performed if:
 - i. Specimen received is insufficient or inappropriate
 - ii. Specimen quality is unsatisfactory
 - iii. Incorrect specimen type
 - iv. Discrepancy between identification on specimen container label and test requisition form

- 5. SRL confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
- 6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.
- 7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.
- 8. Test results cannot be used for Medico legal purposes.
- 9. In case of queries please call customer care (91115 91115) within 48 hours of the report.

SRL Limited

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062

Dr. Akansha Jain Consultant Pathologist





Page 13 Of 13

View Details









akriti Lahs

3 Mahatma Gandhi Marg, Gandhi Nagar Mod Tonk Road, Jaipur (Raj.) Ph.: 0141-2710661

www.aakritilabs.com

CIN NO.: U85195RJ2004PTC019563



Name

Mr. OM PRAKASH

Age/Gender: 34 Y/Male

Patient ID : 012302250020

BarcodeNo : 10077493

Referred By: Self

Registration No: 52723

Registered

: 25/Feb/2023 09:04AM

Analysed

: 25/Feb/2023 11:06AM

Reported

: 25/Feb/2023 11:06AM

Panel

: Medi Wheel (ArcoFemi

Healthcare Ltd)

USG: WHOLE ABDOMEN (Male)

LIVER

: Is normal in size and shape with bright echogenecity.

The IHBR and hepatic radicals are not dilated.

No evidence of focal echopoor/echorich lesion seen. Portal vein diameter and common bile duct appear normal.

GALL

: Is normal in size, shape and echotexture. Walls are smooth and

BLADDER regular with normal thickness. There is no evidence of cholelithiasis.

PANCREAS: Is normal in size, shape and echotexture, Pancreatic duct is not dilated.

SPLEEN

:Is normal in size, shape and echogenecity. Spleenic hilum is not dilated.

KIDNEYS: Right Kidney:-Size: 95 x 46 mm, Left Kidney:-Size: 99 x 38 mm.

Bilateral Kidneys are normal in size, shape and echotexture, corticomedullary differentiation is fair and ratio appears normal.

Pelvi calyceal system is normal. No evidence of hydronephrosis/ nephrolithiasis.

URINARY: Bladder walls are smooth, regular and normal thickness.

BLADDER: No evidence of mass or stone in bladder lumen.

PROSTATE: Is normal in size, shape and echotexture,

measures: 29 x 25 x 24 mm, wt:9 gms.

Its capsule is intact and no evidence of focal lesion.

SPECIFIC: No evidence of retroperitoneal mass or free fluid seen in peritoneal cavity.

No evidence of lymphadenopathy or mass lesion in retroperitoneum.

Visualized bowel loop appear normal. Great vessels appear normal.

IMPRESSION :- Fatty liver

*** End Of Report ***

Page 1 of 1

Dr. Neera Mehta M.B.B.S., D.M.R.D.

RMCNO.005807/14853



Aakriti Labs

3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road, Jaipur (Raj.) Ph.: 0141-2710661 www.aakritilabs.com CIN No. U85195RJ2004PTC019563

Name : Mr. OM PRAKASH

Age/Gender: 34 Y/Male

Patient ID : 012302250020

BarcodeNo: 10077493

Referred By: Self

Registration No: 52723

Registered : 25/Feb/2023 09:04AM

Analysed : 25/Feb/2023 04:20PM

Reported : 25/Feb/2023 04:20PM

Healthcare Ltd)

: Medi Wheel (ArcoFemi

DIGITAL X-RAY CHEST PA VIEW

Panel

Soft tissue shadow and bony cages are normal.

Trachea is central.

Bilateral lung field and both CP angle are clear.

Domes of diaphragm are normally placed.

Transverse diameter of heart appears with normal limits.

IMPRESSION:- NO OBVIOUS ABNORMALITY DETECTED.

*** End Of Report ***

Page 1 of 1


Dr. Neera Mehta M.B.B.S., D.M.R.D. RMCNO.005807/14853



Aakriti Labs
134 / MR. OM PRAKASH / 34 Yrs / M/ Non Smoker
134 / MR. OM PRAKASH / 34 Yrs / M/ Non Smoker
Heart Rate : 73 bpm / Tested On : 25-Feb-23 12.24.17 / HF 0.05 Hz - LF 100 Hz / Notch 50 Hz / Sn 1.00 Cm/mV / Sw 25 mm/s
/ Refd By.: MEDI WHEEL

ECG







Aakriti Labs

3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road, Jaipur (Raj.) Ph.: 0141-2710661 www.aakritilabs.com CIN No. U85195RJ2004PTC019563

NAME	MR OM PRAKASH	AGE	34Y	SEX	MALE	٦
REF BY	MEDIWHEEL	DATE	25/02/2023	REG NO		1

ECHOCARDIOGRAM REPORT

WINDOW- PO	OR/ADEQ	JATE/GO	ODVALVE		_			
MITRAL NOR		NORMAL		TRICUSPID		NORMAL		
AORTIC NOR		NORMAL	F	PULMONAR	1		L	
2D/M-MOD					01			
IVSD mm	9.1		IVSS mm	13.9	13.9 AORTA m		nm 23.0	
LVID mm	40.3		LVIS mm	23.0	LA mn	1	28.4	
LVPWD mm	9.1		LVPWS mm	13.9	EF%		60%	
CHAMBERS								
LA		NO	RMAL	RA		NOF	RMAL	
LV		NO	RMAL	RV		NOF	RMAL	
PERICARDIUM		NO	RMAL					
DOPPLER STUD		51						
PEAK VELOCITY	m/s E/A	1.1	1/0.79	PEAK GRAI	PEAK GRADIANT MmHg			
MEAN VELOCIT	Y m/s			MEAN GRA	MEAN GRADIANT MmHg			
MVA cm2 (PLANITMETERY)		(Y)		MVA cm2	MVA cm2 (PHT)			
MR								
AORTIC				*	4			
PEAK VELOCITY	m/s	1.7	4	PEAK GRAI	DIANT MmHg			
MEAN VELOCIT	Y m/s				MEAN GRADIANT MmHg			
AR								
TRICUSPID								
PEAK VELOCITY	m/s	0.73	3	PEAK GRAD	PEAK GRADIANT MmHg			
MEAN VELOCIT	Y m/s		Y = 1 + 2 = 1		MEAN GRADIANT MmHg			
TR		400		7.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2	PASP mmHg			
PULMONARY			VALLE	IIIM			y and	
PEAK VELOCITY	m/s	1.42	2	PEAK GRAD	DIANT MmHg			
MEAN VELOCIT	Y m/s				MEAN GRADIANT MmHg			
PR			W 15 10	RVEDP mm				

IMPRESSION

- NORMAL LV SYSTOLIC & DIASTOLIC FUNCTION
- **NO RWMA LVEF 60%**
- NORMAL RV FUNCTION
- NORMAL CHAMBER DIMENSIONS
- NORMAL VALVULAR ECHO
- INTACT IAS / IVS
- NO THROMBUS, NO VEGETATION, NORMAL PERICARDIUM.
- **IVC NORMAL**

CONCLUSION: FAIR LV FUNCTION.

Cardiologist